{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:41:01Z","timestamp":1773780061576,"version":"3.50.1"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ctrv.2024.102806","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T15:49:49Z","timestamp":1722268189000},"page":"102806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Antibody-drug conjugates for hepato-pancreato-biliary malignancies: \u201cMagic bullets\u201d to the rescue?"],"prefix":"10.1016","volume":"129","author":[{"given":"Charalampos","family":"Theocharopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis A.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalampos-Christos","family":"Douligeris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Epaminondas","family":"Kolorizos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elissaios","family":"Kontis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: Cancer J Clin"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102806_b0010","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102806_b0015","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"10409","key":"10.1016\/j.ctrv.2024.102806_b0020","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.ctrv.2024.102806_b0025","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline","volume":"38","author":"Gordan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"10126","key":"10.1016\/j.ctrv.2024.102806_b0035","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102806_b0040","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102806_b0050","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102806_b0055","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/annonc\/mdz058","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102806_b0060","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920962997","article-title":"An overview of antibody-drug conjugates in oncological practice","volume":"12","author":"Theocharopoulos","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0065","article-title":"Antibody-drug conjugates: functional principles and applications in oncology and beyond","volume":"9","author":"Theocharopoulos","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0070","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102429","article-title":"Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes","volume":"14","author":"Di Federico","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s44276-024-00038-w","article-title":"Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors","volume":"2","author":"Wu","year":"2024","journal-title":"BJC Reports"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0090","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/liv.15504","article-title":"Immunotherapy in hepatocellular carcinoma: How does underlying liver disease influence therapeutic strategy and outcomes?","volume":"43","author":"Roth","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.ctrv.2024.102806_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102806_b0105","doi-asserted-by":"crossref","first-page":"9182","DOI":"10.1039\/D2CS00446A","article-title":"Non-internalising antibody-drug conjugates","volume":"51","author":"Ashman","year":"2022","journal-title":"Chem Soc Rev"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0110","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41467-018-03880-y","article-title":"Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice","volume":"9","author":"Rossin","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0115","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: Recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0120","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102806_b0125","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102806_b0130","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102806_b0135","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/dmd.119.089276","article-title":"Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells","volume":"48","author":"Sharma","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1208\/s12248-021-00584-y","article-title":"Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor","volume":"23","author":"Bussing","year":"2021","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102806_b0145","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102806_b0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer","volume":"10","author":"Perrone","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0160","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102806_b0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2022.04.039","article-title":"Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?","volume":"171","author":"Corti","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102806_b0175","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2024.102806_b0180","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.12998\/wjcc.v7.i15.1964","article-title":"HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer","volume":"7","author":"Kaito","year":"2019","journal-title":"World J Clin Cases"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MPA.0000000000001479","article-title":"Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States","volume":"49","author":"Barzi","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.ctrv.2024.102806_b0190","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919871126","article-title":"Real-world efficacy and safety of liposomal irinotecan plus fluorouracil\/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group","volume":"11","author":"Yoo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0195","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0200","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/hep.26762","article-title":"Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting","volume":"59","author":"Sirica","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0205","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1124\/jpet.119.262287","article-title":"Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect","volume":"374","author":"Singh","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.neo.2020.12.001","article-title":"Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping","volume":"23","author":"Khera","year":"2021","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102806_b0215","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1021\/bc200158j","article-title":"Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue","volume":"22","author":"Yasunaga","year":"2011","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0220","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1038\/s41598-018-32601-0","article-title":"Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin","volume":"8","author":"Fuchigami","year":"2018","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102806_b0225","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1158\/1535-7163.MCT-21-0335","article-title":"Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer","volume":"20","author":"Tsujii","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2024.102806_b0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41417-024-00764-w","article-title":"Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications","author":"Safri","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0235","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/cancers16010002","article-title":"Digging into the NGS Information from a Large-Scale South European Population with Metastatic\/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction","volume":"16","author":"Ziogas","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2024.102806_b0240","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/cells12060846","article-title":"Heterogeneity of Cholangiocarcinoma Immune Biology","volume":"12","author":"Vita","year":"2023","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102806_b0245","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s00262-012-1278-5","article-title":"B7\u2013H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence","volume":"61","author":"Sun","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0250","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3109\/07357907.2014.909826","article-title":"B7\u2013H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression","volume":"32","author":"Wang","year":"2014","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2024.102806_b0255","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10147-011-0361-9","article-title":"Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma","volume":"18","author":"Kondo","year":"2013","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1756-9966-32-16","article-title":"Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma","volume":"32","author":"Chu","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102806_b0270","first-page":"5179","article-title":"A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma","volume":"33","author":"Lee","year":"2013","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0275","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/hepr.12320","article-title":"Expression and clinical implications of HAb18G\/CD147 in hepatocellular carcinoma","volume":"45","author":"Zhu","year":"2015","journal-title":"Hepatol Res"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0280","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1054\/bjoc.2000.1580","article-title":"Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma","volume":"84","author":"Ito","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102806_b0285","doi-asserted-by":"crossref","first-page":"e15166","DOI":"10.1200\/jco.2015.33.15_suppl.e15166","article-title":"Stem cell surface markers CD133 expression in hepatocellular carcinoma and as single prognostic factor for liver transplantation","volume":"33","author":"Li","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2024.102806_b0290","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1158\/1078-0432.CCR-09-0151","article-title":"CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery","volume":"15","author":"Yang","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0295","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1309\/HCQWPWD50XHD2DW6","article-title":"Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples","volume":"129","author":"Baumhoer","year":"2008","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0305","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102806_b0310","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","article-title":"High expression of TROP2 correlates with poor prognosis in pancreatic cancer","volume":"99","author":"Fong","year":"2008","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0315","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1186\/s12885-016-2889-6","article-title":"The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer: HER1-4 protein expression and prognosis in pancreatic cancer","volume":"16","author":"Li","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0320","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.5301\/jbm.5000157","article-title":"HER family receptor expression and prognosis in pancreatic cancer","volume":"30","author":"Bittoni","year":"2015","journal-title":"Int J Biol Markers"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0325","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/sj.bjc.6605375","article-title":"Clinical importance of B7\u2013H3 expression in human pancreatic cancer","volume":"101","author":"Yamato","year":"2009","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102806_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7070172","article-title":"Tumor B7\u2013H3 (CD276) Expression and Survival in Pancreatic Cancer","volume":"7","author":"Inamura","year":"2018","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0335","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1475-2867-13-81","article-title":"Correlation between B7\u2013H3 expression and matrix metalloproteinases 2 expression in pancreatic cancer","volume":"13","author":"Xu","year":"2013","journal-title":"Cancer Cell Int"},{"issue":"2B","key":"10.1016\/j.ctrv.2024.102806_b0340","first-page":"1399","article-title":"Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma","volume":"28","author":"Pryczynicz","year":"2008","journal-title":"Anticancer Res"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102806_b0345","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.26661","article-title":"Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma","volume":"118","author":"Valsecchi","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0350","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/cam4.1064","article-title":"Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma","volume":"6","author":"Lu","year":"2017","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0355","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int J Med Sci"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102806_b0360","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/07357907.2021.1943747","article-title":"Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness","volume":"39","author":"Weidemann","year":"2021","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2024.102806_b0365","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.2020.38.4_suppl.713","article-title":"Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers","volume":"38","author":"Ko","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0370","doi-asserted-by":"crossref","first-page":"e32882","DOI":"10.1097\/MD.0000000000032882","article-title":"The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes","volume":"102","author":"Kayikcioglu","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0375","first-page":"1031","article-title":"Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients","volume":"37","author":"Zhang","year":"2022","journal-title":"Histol Histopathol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102806_b0380","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/jclinpath-2011-200400","article-title":"Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation","volume":"65","author":"Soini","year":"2012","journal-title":"J Clin Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0385","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-06-2351","article-title":"Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer","volume":"13","author":"Khorana","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0390","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/jcp.39.6.610","article-title":"Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry","volume":"39","author":"Allum","year":"1986","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2024.102806_b0395","article-title":"HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0400","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-023-00447-z","article-title":"Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma","volume":"7","author":"Zhu","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102806_b0405","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1158\/1535-7163.MCT-21-0015","article-title":"Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma","volume":"20","author":"Yokota","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0410","article-title":"New Emerging Targets in Cancer Immunotherapy: The Role of B7\u2013H3","volume":"12","author":"Koumprentziotis","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102806_b0415","first-page":"4315","article-title":"High expression of B7\u2013H2 or B7\u2013H3 is associated with poor prognosis in hepatocellular carcinoma","volume":"19","author":"Zheng","year":"2019","journal-title":"Mol Med Rep"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102806_b0420","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7\u2013H3 for Solid Cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102806_b0425","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jacsau.2c00448","article-title":"40 Years of Duocarmycins: A Graphical Structure\/Function Review of Their Chemical Evolution, from SAR to Prodrugs and ADCs","volume":"2","author":"Felber","year":"2022","journal-title":"JACS Au"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102806_b0430","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jcph.148","article-title":"Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors","volume":"53","author":"Xin","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"52","key":"10.1016\/j.ctrv.2024.102806_b0435","doi-asserted-by":"crossref","first-page":"90351","DOI":"10.18632\/oncotarget.20087","article-title":"Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102806_b0440","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102806_b0445","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3389\/fonc.2019.00717","article-title":"High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma","volume":"9","author":"Ma","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102806_b0450","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/00498254.2018.1534030","article-title":"Preclinical pharmacokinetics of a novel anti-c-Met antibody-drug conjugate, SHR-A1403, in rodents and non-human primates","volume":"49","author":"Yang","year":"2019","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102806_b0455","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41401-018-0198-0","article-title":"SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models","volume":"40","author":"Yang","year":"2019","journal-title":"Acta Pharmacol Sin"},{"issue":"7_Supplement","key":"10.1016\/j.ctrv.2024.102806_b0460","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1158\/1538-7445.AM2023-6311","article-title":"Abstract 6311: ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors","volume":"83","author":"Reilly","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102806_b0465","doi-asserted-by":"crossref","first-page":"1238051","DOI":"10.3389\/fonc.2023.1238051","article-title":"CD147: an integral and potential molecule to abrogate hallmarks of cancer","volume":"13","author":"Nyalali","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102806_b0470","doi-asserted-by":"crossref","first-page":"5019367","DOI":"10.1155\/2017\/5019367","article-title":"CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis","volume":"2017","author":"Peng","year":"2017","journal-title":"Biomed Res Int"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0475","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.nano.2017.09.012","article-title":"Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes","volume":"14","author":"Wang","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ctrv.2024.102806_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119527","article-title":"A comprehensive review on time-tested anticancer drug doxorubicin","volume":"278","author":"Sritharan","year":"2021","journal-title":"Life Sci"},{"issue":"6 Suppl 13","key":"10.1016\/j.ctrv.2024.102806_b0485","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0490","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.apsb.2018.05.010","article-title":"Understanding the biology of HER3 receptor as a therapeutic target in human cancer","volume":"8","author":"Lyu","year":"2018","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0495","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-016-0402-3","article-title":"Heregulin-1ss and HER3 in hepatocellular carcinoma: status and regulation by insulin","volume":"35","author":"Buta","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0500","article-title":"The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma","volume":"10","author":"Caviglia","year":"2021","journal-title":"Biology (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0505","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1593\/tlo.13475","article-title":"EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo","volume":"6","author":"Sala","year":"2013","journal-title":"Transl Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0510","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3892\/or.2020.7893","article-title":"EV20-sss-vc\/MMAF, an HER-3 targeting antibody-drug conjugate displays antitumor activity in liver cancer","volume":"45","author":"D'Agostino","year":"2021","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0515","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40169-018-0198-1","article-title":"The role of CD133 in cancer: a concise review","volume":"7","author":"Glumac","year":"2018","journal-title":"Clin Transl Med"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0520","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/15384047.2021.1916381","article-title":"The role of CD133 in hepatocellular carcinoma","volume":"22","author":"Liu","year":"2021","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102806_b0525","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","article-title":"CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway","volume":"27","author":"Ma","year":"2008","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0530","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bbrc.2020.03.009","article-title":"Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133(+) cells to vincristine and 5-fluorouracil through upregulation of BBC3","volume":"525","author":"Hemati","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102806_b0535","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1742-1241.2008.01777.x","article-title":"Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma","volume":"62","author":"Song","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0540","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/sj.bjc.6604437","article-title":"CD133\/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers","volume":"99","author":"Smith","year":"2008","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0545","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjug Chem"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0550","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1566523220666200623170738","article-title":"CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy","volume":"20","author":"Ni","year":"2020","journal-title":"Curr Gene Ther"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0555","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00432-017-2436-0","article-title":"Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo","volume":"143","author":"Ma","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102806_b0560","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/0008-5472.CAN-18-2839","article-title":"Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma","volume":"79","author":"Sun","year":"2019","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0565","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.livres.2020.11.003","article-title":"Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma(\u2606)","volume":"4","author":"Shih","year":"2020","journal-title":"Liver Res"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102806_b0570","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","article-title":"Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma","volume":"100","author":"Shirakawa","year":"2009","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0575","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0580","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102806_b0585","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.21037\/atm-22-5976","article-title":"A literature review of the promising future of TROP2: a potential drug therapy target","volume":"10","author":"Wen","year":"2022","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0590","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102806_b0595","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2\/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0600","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1535-7163.MCT-11-0115","article-title":"Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models","volume":"10","author":"Sharkey","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102806_b0605","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"10.1016\/j.ctrv.2024.102806_b0610","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10.1016\/j.ctrv.2024.102806_b0615","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"10.1016\/j.ctrv.2024.102806_b0620","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000333825","article-title":"HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer","volume":"81","author":"Hirakawa","year":"2011","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102806_b0625","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/1535-7163.MCT-23-0198","article-title":"AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors","volume":"22","author":"Weng","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0630","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2159-8290.CD-22-1368","article-title":"Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer","volume":"13","author":"Weng","year":"2023","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0635","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040483","article-title":"EV20\/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors","volume":"13","author":"Capone","year":"2021","journal-title":"Pharmaceutics"},{"issue":"13_Supplement","key":"10.1016\/j.ctrv.2024.102806_b0640","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1158\/1538-7445.AM2018-734","article-title":"Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation","volume":"78","author":"Caruso","year":"2018","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102806_b0645","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/ijc.32273","article-title":"An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer","volume":"145","author":"Bourillon","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0650","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12885-022-09294-w","article-title":"Co-deficiency of B7\u2013H3 and B7\u2013H4 identifies high CD8 + T cell infiltration and better prognosis in pancreatic cancer","volume":"22","author":"Si","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102806_b0655","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.615691","article-title":"Cancer Cell B7\u2013H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer","volume":"11","author":"Geerdes","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102806_b0660","doi-asserted-by":"crossref","first-page":"27528","DOI":"10.1038\/srep27528","article-title":"Soluble B7\u2013H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4\/NF-kappaB pathway","volume":"6","author":"Xie","year":"2016","journal-title":"Sci Rep"},{"issue":"43","key":"10.1016\/j.ctrv.2024.102806_b0665","doi-asserted-by":"crossref","first-page":"74856","DOI":"10.18632\/oncotarget.20421","article-title":"B7\u2013H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0670","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers3021513","article-title":"Epidermal growth factor receptor in pancreatic cancer","volume":"3","author":"Oliveira-Cunha","year":"2011","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0675","first-page":"5361","article-title":"EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival","volume":"17","author":"Fagman","year":"2019","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0680","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41416-020-01046-6","article-title":"Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer","volume":"123","author":"Greene","year":"2020","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102806_b0685","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CJI.0b013e3182562d76","article-title":"Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation","volume":"35","author":"Luedke","year":"2012","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0690","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11523-018-0616-8","article-title":"Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy","volume":"14","author":"Li","year":"2019","journal-title":"Target Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102806_b0695","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1021\/acs.jmedchem.1c01920","article-title":"Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer","volume":"65","author":"Zhu","year":"2022","journal-title":"J Med Chem"},{"issue":"71","key":"10.1016\/j.ctrv.2024.102806_b0700","doi-asserted-by":"crossref","first-page":"33446","DOI":"10.18632\/oncotarget.26002","article-title":"RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models","volume":"9","author":"Wong","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102806_b0705","doi-asserted-by":"crossref","first-page":"C846","DOI":"10.1152\/ajpcell.00290.2021","article-title":"Role of glypican-1 in regulating multiple cellular signaling pathways","volume":"321","author":"Pan","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0710","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.asjsur.2012.08.001","article-title":"GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer","volume":"36","author":"Duan","year":"2013","journal-title":"Asian J Surg"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102806_b0715","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-020-0781-2","article-title":"Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer","volume":"122","author":"Nishigaki","year":"2020","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102806_b0720","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.neo.2021.07.006","article-title":"A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma","volume":"23","author":"Munekage","year":"2021","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0725","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: An Immunotherapeutic Target beyond Solid Tumors","volume":"14","author":"Faust","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102806_b0730","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0735","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102806_b0740","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102806_b0745","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102806_b0750","doi-asserted-by":"crossref","first-page":"TPS540","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS540","article-title":"An open-label, phase II study of intravenous anetumab ravtansine, an anti-mesothelin antibody drug conjugate, in pretreated mesothelin-expressing advanced pancreatic cancer","volume":"36","author":"Chokshi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102806_b0755","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1200\/JCO.2022.40.16_suppl.4136","article-title":"Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208","volume":"40","author":"Spiliopoulou","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102806_b0760","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tibs.2018.09.008","article-title":"The Claudins: From Tight Junctions to Biological Systems","volume":"44","author":"Tsukita","year":"2019","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0765","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ijc.28400","article-title":"Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms","volume":"134","author":"Woll","year":"2014","journal-title":"Int J Cancer"},{"issue":"13_Supplement","key":"10.1016\/j.ctrv.2024.102806_b0770","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/1538-7445.AM2021-1204","article-title":"Abstract 1204: SO-N102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels","volume":"81","author":"Sadilkova","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102806_b0775","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2023.41.4_suppl.352","article-title":"A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant\/refractory solid tumors","volume":"41","author":"Xu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7_Supplement","key":"10.1016\/j.ctrv.2024.102806_b0780","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/1538-7445.AM2023-6300","article-title":"Therapeutic potential of EO-3021\/SYSA1801, a Claudin 18.2 antibody-drug conjugate, for the treatment of CLDN18. 2-expressing cancers","volume":"83","author":"Dan","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102806_b0785","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2023.41.16_suppl.3016","article-title":"First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant\/refractory solid tumors","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102806_b0790","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/bjs.1800820831","article-title":"Tissue factor expression correlates with histological grade in human pancreatic cancer","volume":"82","author":"Kakkar","year":"1995","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0795","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jth.12442","article-title":"Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice","volume":"12","author":"Yokota","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102806_b0800","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1182\/blood-2003-10-3417","article-title":"Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration","volume":"103","author":"Hjortoe","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0805","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3892\/or.2020.7850","article-title":"Antitumor effect of humanized anti-tissue factor antibody-drug conjugate in a model of peritoneal disseminated pancreatic cancer","volume":"45","author":"Tsumura","year":"2021","journal-title":"Oncol Rep"},{"issue":"35","key":"10.1016\/j.ctrv.2024.102806_b0810","doi-asserted-by":"crossref","first-page":"59086","DOI":"10.18632\/oncotarget.19175","article-title":"Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2024.102806_b0815","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S0959-8049(22)01043-7","article-title":"A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage","volume":"174","author":"Ulahannan","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102806_b0820","doi-asserted-by":"crossref","first-page":"583","DOI":"10.7150\/ijms.32751","article-title":"Expression of chosen carcinoembryonic-related cell adhesion molecules in pancreatic intraepithelial neoplasia (PanIN) associated with chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC)","volume":"16","author":"Dorf","year":"2019","journal-title":"Int J Med Sci"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102806_b0825","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-09-0586","article-title":"CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates","volume":"15","author":"Govindan","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102806_b0830","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0835","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102806_b0840","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102806_b0845","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102806_b0850","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"12","author":"de Vries","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2024.102806_b0855","article-title":"Genomic characterization of ERBB2-driven biliary cancer and a case of response to ado-trastuzumab emtansine","volume":"3","author":"Mondaca","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102806_b0860","article-title":"Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2-overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study","volume":"10","author":"Lavingia","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.ctrv.2024.102806_b0865","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7_Supplement","key":"10.1016\/j.ctrv.2024.102806_b0870","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1158\/1538-7445.AM2023-2702","article-title":"Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0875","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102806_b0880","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/15384047.2016.1139248","article-title":"An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer","volume":"17","author":"Li","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ctrv.2024.102806_b0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0890","first-page":"175","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib Ther"},{"key":"10.1016\/j.ctrv.2024.102806_b0895","article-title":"Core Fucosylation Regulates the Function of Pre-BCR, BCR and IgG in Humoral Immunity","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102806_b0900","doi-asserted-by":"crossref","first-page":"TPS1101","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1101","article-title":"First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed\/refractory solid tumors","volume":"38","author":"Li","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0905","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/JLB.2MR0220-549R","article-title":"ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis","volume":"108","author":"Bui","year":"2020","journal-title":"J Leukoc Biol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0910","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.4049\/jimmunol.0903244","article-title":"Acute hypoxia induces HIF-independent monocyte adhesion to endothelial cells through increased intercellular adhesion molecule-1 expression: the role of hypoxic inhibition of prolyl hydroxylase activity for the induction of NF-kappa B","volume":"185","author":"Winning","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0915","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.bbrc.2007.08.074","article-title":"Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin\/catenin complex formation","volume":"362","author":"Yuan","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102806_b0920","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1050-1738(01)00157-8","article-title":"Interactions of intercellular adhesion molecule-1 with fibrinogen","volume":"12","author":"Tsakadze","year":"2002","journal-title":"Trends Cardiovasc Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:01:51Z","timestamp":1723680111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":184,"alternative-id":["S0305737224001348"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102806","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-drug conjugates for hepato-pancreato-biliary malignancies: \u201cMagic bullets\u201d to the rescue?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102806"}}